eMERGE is a national network organized and funded by the National Human Genome Research Institute (NHGRI) that combines DNA biorepositories with electronic medical record (EMR) systems for large scale, high-throughput genetic research in support of implementing genomic medicine.
Many factors contribute to risk of a disease. Some of these factors are internal, like genetics, and others are external, like where someone lives. Over the last several years researchers have discovered that in addition to one gene being associated with a given disease (monogenic factors), many genes across your genome can contribute to the development of a disease (polygenic factors). To learn more about elements that contribute to risk a disease, click here.
The All of Us is promoting two new funding opportunities designed to support data analysis using the Researcher Workbench
May 5, 2022 9:10 PM
Today in Nature Medicine: GenoVA Study Report
April 4, 2022 5:55 PM
NIH Cloud Platform Interoperability Administrative Coordinating Center
March 3, 2022 4:09 PM
The University of Colorado is studying relationships among different types of outcomes important to health services and implementation practitioners and researchers
March 3, 2022 7:52 PM
All of Us Researchers Convention
March 3, 2022 7:36 PM
Notice of Special Interest: Development and Implementation of Clinical Informatics Tools to Enhance Patients’ Use of Genomic Information
January 1, 2022 5:50 PM
Slaby I, Hain HS, Abrams D, Mentch FD, Hakonarson H. An electronic health record (EHR) phenotype algorithm to identify patients with attention deficit hyperactivity disorders (ADHD) and psychiatric comorbidities. Journal of neurodevelopmental disorders. 2022 Jun 11;14(1):37.
Taub MA, Conomos MP, Keener R, Iyer KR, Mathias RA, et al. Genetic determinants of telomere length from 109,122 ancestrally diverse whole-genome sequences in TOPMed. Cell genomics. 2022 Jan 12;2(1).
Sunthankar SD, Kannankeril PJ, Gaedigk A, Radbill AE, Van Driest SL. Influence of CYP2D6 genetic variation on adverse events with propafenone in the pediatric and young adult population. Clinical and translational science. 2022 May 5;.